Zobrazeno 1 - 10
of 240
pro vyhledávání: '"35"'
Autor:
Angelique A. C. Lemckert, Jos M. Grimbergen, Irma Damen, Marco G. Cecchini, Germaine Penders, Niels Helmus, David Zuijdgeest, Michelle van Meerendonk, Wouter Koudstaal, Olga J.A.E Ophorst, Abraham Bout, Richard van Rijnsoever, Jaap Goudsmit, Antoinette Wetterwald, Björn F. Koel, Eric Hartkoorn, Marie-Pierre de Béthune, Ronald Vogels, Stefan Kostense, Laura Panitti, Mieke Caroline Sprangers, Menzo J. E. Havenga, Paul H.A. Quax
Publikováno v:
Journal of virology, 77(15), 8263-8271. American Society for Microbiology
Journal of Virology, 15, 77, 8263-8271
Journal of Virology, 15, 77, 8263-8271
Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However, preexisting immunity against Ad5 hampers consistency of
Autor:
Pengju Li, Xiangrui Li, Yuanyuan Liang, Yuhua Li, Zhenchao Zhang, Xiaoxu Nan, Qingqing Liu, Gaigai Hong, Qing Xie, Shuai Wang
Publikováno v:
Veterinary parasitology. 260
Toxoplasma gondii rhoptry proteins (TgROPs) have been considered the main targets and indicator molecules for immune diagnosis and prophylaxis because they present during the initial process of invasion. The aim of this study was to evaluate the prot
Autor:
K-Q Xin, N Jounai, K Someya, K Honma, H Mizuguchi, S Naganawa, K Kitamura, T Hayakawa, S Saha, F Takeshita, K Okuda, M Honda, D M Klinman
Publikováno v:
Gene Therapy. 12:1769-1777
Immunization involving a DNA vaccine prime followed by an adenovirus type 5 (Ad5) boost elicited a protective immune response against SHIV challenge in monkeys. However, the hepatocellular tropism of Ad5 limits the safety of this viral vector. This s
Adenovirus (Ad) vaccine vectors have proven highly immunogenic in multiple experimental models, but the innate immune responses induced by these vectors remain poorly characterized. Here we report innate cytokine responses to 5 different Ad vectors i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe340cd2811b9dc80e7a2bcb70fd4f7
https://europepmc.org/articles/PMC3446581/
https://europepmc.org/articles/PMC3446581/
Autor:
Gert Gillissen, Marjolein van der Meer, Katarina Radosevic, Jaap Goudsmit, Ariane Rodriguez, Rie von Eyben, Maria Grazia Pau, Carolien Warnar, Angelique A. C. Lemckert
Publikováno v:
Clinical and vaccine immunology, 17(11), 1687-1694. American Society for Microbiology
The most advanced malaria vaccine, RTS,S, is comprised of an adjuvant portion of the Plasmodium falciparum circumsporozoite (CS) protein fused to and admixed with the hepatitis B virus surface antigen. This vaccine confers short-term protection again
Autor:
Papa Toure, Anuj Gaggar, Robert Strauss, Branka Horvat, Nancy B. Kiviat, Shaoheng Ni, Nelson DiPaolo, Daniel Stone, Salif Sow, Zong Yi Li, Sebastian Tuve, Dmitry M. Shayakhmetov, André Lieber
In contrast to commonly used serotype 5-based adenovirus (Ad) vectors, Ad's containing fibers derived from B-group serotype 35 (Ad5/35) efficiently transduce human DCs ex vivo and appear to target antigen-presenting cells after intravenous injection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a442e57021f54a58456c4fd03786c6
https://europepmc.org/articles/PMC1424671/
https://europepmc.org/articles/PMC1424671/
Autor:
Rik L. de Swart, Mieke Caroline Sprangers, Jaap Goudsmit, Menzo J. E. Havenga, Sandra Verhaagh, Stefan Kostense, Alexander N. Zakhartchouk, Selma Yüksel, Marja Van Meijer, Geert van Amerongen, Olga J.A.E Ophorst, Albert D. M. E. Osterhaus
Publikováno v:
Vaccine, 22, 3035-3044. Elsevier
Vaccine, 22(23-24), 3035-3044. Elsevier BV
Vaccine, 22(23-24), 3035-3044. Elsevier BV
Substituting the coat proteins of adenoviral vector serotype 5 (Ad5) can alter vector tropism and circumvent vector neutralization. Here we report that an Ad5 vector carrying a part of the fiber molecule of human subgroup B adenovirus serotype 35 (Ad
Publikováno v:
J Virol
Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infection in infants and young children. The vaccine-enhanced disease (VED) has greatly hindered the development of an RSV vaccine. Currently, there are no licen
Publikováno v:
Clinical and Experimental Immunology
Clinical and Experimental Immunology, 2001, 126 (3), pp.482-487. ⟨10.1046/j.1365-2249.2001.01708.x⟩
Clinical and Experimental Immunology, Wiley, 2001, 126 (3), pp.482-487. ⟨10.1046/j.1365-2249.2001.01708.x⟩
Clinical and Experimental Immunology, 2001, 126 (3), pp.482-487. ⟨10.1046/j.1365-2249.2001.01708.x⟩
Clinical and Experimental Immunology, Wiley, 2001, 126 (3), pp.482-487. ⟨10.1046/j.1365-2249.2001.01708.x⟩
SummaryA range of strategies are being explored to develop more effective vaccines against mycobacterial infection, including immunization with DNA plasmids encoding single mycobacterial bacterial genes and the use of recombinant live vectors based o
Autor:
Valeria Listorti, Caterina Lupini, Viviana Felice, Mattia Cecchinato, Giulia Mescolini, Flavio Silveira, Elena Catelli, Giacomo Berto
Publikováno v:
Transboundary and Emerging Diseases. 67:1025-1031
Recently, a new genotype of infectious bursal disease virus (IBDV), named ITA, was detected in IBD-vaccinated Italian broilers. Genome characterization revealed ITA to be a genetically different IBDV, belonging to genogroup 6 according to a recently